| Original language | English (US) |
|---|---|
| Pages (from-to) | 1094-1097 |
| Number of pages | 4 |
| Journal | JACC: Cardiovascular Imaging |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2018 |
Bibliographical note
Funding Information:Dr. Dang has received research funding to her institution from Roche/Genentech and PUMA. Dr. Lynce has received research support from Genentech, Pfizer, Bristol-Myers Squibb, and AstraZeneca. Dr. Swain has received honoraria and travel support from Roche; consulting support from AstraZeneca for DMC no payment to date, Genentech/Roche, Pieris Pharmaceuticals, and Inivata; travel/accommodations/expenses from Genentech/Roche, Inivata, and Caris; and investigator meeting meal from Novartis. Dr. Dent has received support from Hoffman La Roche. Dr. Blaes has reported that she has no relationships relevant to the contents of this paper to disclose.
Keywords
- breast cancer
- cardiotoxicity
- trastuzumab
